1.Hypersensitivity reaction to chloroquine, 4-aminoquinolines or azithromycin and ivermectin 2.Shortness of breath in resting position 3. Known prolonged QT syndrome 4. Active or clinically significant cardiac disease including congestive heart failure. 5. History or current evidence of clinically significant cardiac arrhythmia, atrial fibrillation or paroxysmal supraventricular tachycardia 6. Use of concomitant medications that prolong the QT/QTc interval 7. Elevated levels of troponin I, Creatinine kinase MB, and Myoglobin 8. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency 9. Already receiving chloroquine or azithromycin 10. Patients with other viral pneumonia 11. Patients who have received organ transplantation or surgery planning in the past 6 months 12. Patients who can't take food or drugs due to coma or intestinal obstruction 13. Patients who have severe underlying diseases that affect survival including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding and severe malnutrition 14. Patients that are pregnant or lactating 15. Patients (including male Patients) having a pregnancy plan (including plans for sperm donation or egg donation) 16. Patients that may fail to take effective contraceptive measures within the next 6 months 17. Patients with allergies to macrolides and chloroquine tablets 18. Patients with contraindications to the test drugs. 19. Patients who are using drugs that interact with the test drugs. 20. Patients using drugs associated with severe and/or life-threatening events [with a narrow therapeutic index] 21. Patients with cirrhosis or pancreatitis 22. Patients with Creatinine QUOTE >110 umol/l 23. Patients with decreased liver function 24. Patients who in the opinion of the investigators after assessing all relevant parameters are unsuitable for the study.

1.Hypersensitivity reaction to chloroquine, 4-aminoquinolines or azithromycin and ivermectin 2.Shortness of breath in resting position 3. Known prolonged QT syndrome 4. Active or clinically significant cardiac disease including congestive heart failure. 5. History or current evidence of clinically significant cardiac arrhythmia, atrial fibrillation or paroxysmal supraventricular tachycardia 6. Use of concomitant medications that prolong the QT/QTc interval 7. Elevated levels of troponin I, Creatinine kinase MB, and Myoglobin 8. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency 9. Already receiving chloroquine or azithromycin 10. Patients with other viral pneumonia 11. Patients who have received organ transplantation or surgery planning in the past 6 months 12. Patients who can't take food or drugs due to coma or intestinal obstruction 13. Patients who have severe underlying diseases that affect survival including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding and severe malnutrition 14. Patients that are pregnant or lactating 15. Patients (including male Patients) having a pregnancy plan (including plans for sperm donation or egg donation) 16. Patients that may fail to take effective contraceptive measures within the next 6 months 17. Patients with allergies to macrolides and chloroquine tablets 18. Patients with contraindications to the test drugs. 19. Patients who are using drugs that interact with the test drugs. 20. Patients using drugs associated with severe and/or life-threatening events [with a narrow therapeutic index] 21. Patients with cirrhosis or pancreatitis 22. Patients with Creatinine QUOTE >110 umol/l 23. Patients with decreased liver function 24. Patients who in the opinion of the investigators after assessing all relevant parameters are unsuitable for the study.